Navtemadlin

Navtemadlin (AMG 232) is a potent, selective and orally available inhibitor of p53-MDM2 interaction, with an IC50 of 0.6 nM. Navtemadlin binds to MDM2 with a Kd of 0.045 nM[1][2].

Product Specifications

CAS Number

[1352066-68-2]

Product Name Alternative

AMG 232; KRT-232

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

E1/E2/E3 Enzyme; MDM-2/p53

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/AMG-232.html

Purity

99.61

Solubility

DMSO : ≥ 50 mg/mL

Smiles

O=C(O)C[C@]1(C)C(N([C@H](CS(=O)(C(C)C)=O)C(C)C)[C@H](C2=CC=C(Cl)C=C2)[C@@H](C3=CC=CC(Cl)=C3)C1)=O

Molecular Formula

C28H35Cl2NO5S

Molecular Weight

568.55

Precautions

H302, H312, H332

References & Citations

[1]Canon J, et al. The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents. Mol Cancer Ther. 2015 Mar;14 (3) :649-58.|[2]Rew Y, et al. Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer. J Med Chem. 2014 Aug 14;57 (15) :6332-41.